• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    OKYO Pharma Limited - Ordinary Shares (NQ: OKYO )

    1.141 +0.011 (+0.96%)
    Streaming Delayed Price Updated: 10:24 AM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about OKYO Pharma Limited - Ordinary Shares

    < Previous 1 2 3 Next >
    OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Chairman Acquires Shares
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Chairman Acquires Shares
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma CEO Interview to Air on Bloomberg TV
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Chairman Acquires Shares
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    OKYO Pharma Announces Chairman Acquires Shares
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Participation in May 2024 Investor Conferences
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
    Top-line Efficacy and Safety Data on Track for Release in December 2023 
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma’s Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)
    Via AB Newswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.